Cargando…
Imatinib Enhances Functional Outcome after Spinal Cord Injury
We investigated whether imatinib (Gleevec®, Novartis), a tyrosine kinase inhibitor, could improve functional outcome in experimental spinal cord injury. Rats subjected to contusion spinal cord injury were treated orally with imatinib for 5 days beginning 30 minutes after injury. We found that imatin...
Autores principales: | Abrams, Mathew B., Nilsson, Ingrid, Lewandowski, Sebastian A., Kjell, Jacob, Codeluppi, Simone, Olson, Lars, Eriksson, Ulf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378614/ https://www.ncbi.nlm.nih.gov/pubmed/22723886 http://dx.doi.org/10.1371/journal.pone.0038760 |
Ejemplares similares
-
Repositioning imatinib for spinal cord injury
por: Kjell, Jacob, et al.
Publicado: (2015) -
Delayed Imatinib Treatment for Acute Spinal Cord Injury: Functional Recovery and Serum Biomarkers
por: Kjell, Jacob, et al.
Publicado: (2015) -
Spatial and Cellular Characterization of mTORC1 Activation after Spinal Cord Injury Reveals Biphasic Increase Mainly Attributed to Microglia/Macrophages
por: Kjell, Jacob, et al.
Publicado: (2014) -
Rat models of spinal cord injury: from pathology to potential therapies
por: Kjell, Jacob, et al.
Publicado: (2016) -
Improved recovery from spinal cord injury in rats with chronic parvovirus serotype-1a infection
por: Kjell, J, et al.
Publicado: (2016)